SPOTLIGHT: Merck exec denies Vioxx payola

Merck's former marketing chief defended the company's practice of giving research grants to doctors, denying that it was an attempt to generate positive buzz for Vioxx with the payouts. The testimony came in the first of thousands of Vioxx cases to go to trial. Story

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.